Business, energy, technology, markets and global industry news from Business News Today

U.S. drug pricing

PharmaDeviceNews U.S. drug pricing
Representative image illustrating the rising focus on U.S. drug pricing reform, as pharmaceutical companies like GSK move to expand access to asthma and COPD medicines through lower costs and direct purchasing models.
Pharma & Biotech

GSK strikes deal with U.S. to lower asthma and COPD drug prices and avoid tariffs

GSK plc’s latest agreement with the United States Administration to lower the price of respiratory medicines, including its inhaled asthma and chronic obstructive pulmonary disease (COPD) portfolio, signals a shift in how global pharmaceutical companies are choosing to respond to increasing U.S. political pressure around drug affordability. The agreement, announced on December 22, 2025, satisfies

Read More
Representative image illustrating Boehringer Ingelheim’s $10B U.S. expansion and participation in TrumpRx.gov, highlighting the intersection of pharmaceutical manufacturing, direct drug pricing, and U.S. government policy.
Pharma & Biotech

Why Boehringer’s $10bn U.S. investment and TrumpRx deal may reshape pharma cost dynamics

Boehringer Ingelheim’s $10B U.S. investment and TrumpRx.gov deal may redefine drug pricing and supply chains. Find out what this changes for pharma now.

Read More